Workshop Pharma 1

Requirements for disclosure of utility or industrial applicability and ramifications for patent validity

Tuesday, September 16, 2014
09.00 - 10.30 h

Speaker:
Jürgen Meier  (Germany)

Curriculum Vitae

Jürgen Meier

Dr. Jürgen Meier  
Vossius & Partner, Munich, Germany

Jürgen Meier is a partner of IP law firm Vossius & Partner in Munich. He is a European patent attorney and is also admitted to practise as a German Patent Attorney and a European Trademark and Design Attorney. Dr Meier represents clients before the European Patent Office (EPO), the German Patent and Trademark Office, the Federal
Patent Court and the German District Courts. He has particular expertise in patent prosecution, opposition and appeal proceedings (in particular relating to molecular biology, pharmaceuticals/vaccines, stem cell technology and biocomputing) and he frequently represents clients in patent disputes before the German courts, including the Federal Supreme Court. Dr Meier also advises clients on the development and maintenance of patent portfolios as well as on questions relating to remunerations for employees’ inventions and responsibilities under the German Act on Employees Invention. His clients comprise multinational enterprises, SMEs, academic institutions, as well as start-up companies.

Dr Meier studied biology and biochemistry at the universities of Freiburg (Germany), Sussex (England) and Dundee (Scotland). His scientific background is cell biology, molecular biology and neurosciences. After completion of his PhD at the European Molecular Biology Laboratory in Heidelberg, he worked for several years at the Centre de Recherche en Neuroscience of McGill University (Canada).

Dr Meier regularly lectures at the Centre d’Etudes Internationales de la Propriété Industrielle of the University of Strasbourg, the Management Centre in Innsbruck, the University of Wuerzburg and the Zeppelin University in Friedrichshafen. In addition to his frequent articles and publications in the IP field, he is often an invited speaker at national and international conferences. He is co-author of the fifth edition of “From Clones to Claims” on the EPO’s jurisdiction in the field of biotechnology in comparison to the US and Japanese practice.